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As genital Chlamydia trachomatis (chlamydia) infec-
tion is often asymptomatic, surveillance of diagnosed 
cases is heavily influenced by the rate and distribu-
tion of testing. In 2007, we started supplementing 
case-based surveillance data from the Norwegian 
Surveillance System for Communicable Diseases 
(MSIS) with aggregated data on age group and sex of 
individuals tested. In this report, annual testing rates, 
diagnosis rates and proportion positive for chlamydia 
in Norway between 1990 and 2013 are presented. From 
2007, rates are also stratified by age group and sex. 
The annual testing rate for chlamydia culminated in 
the early 1990s, with 8,035 tested per 100,000 popu-
lation in 1991. It then declined to 5,312 per 100,000 
in 2000 after which it remained relatively stable. 
Between 1990 and 2013 the annual rate of diagnosed 
cases increased 1.5 times from ca 300 to ca 450 per 
100,000 population. The proportion of positive among 
the tested rose twofold from ca 4% in the 1990s to 8% 
in 2013. Data from 2007 to 2013 indicate that more 
women than men were tested (ratio: 2.56; 95% con-
fidence interval (CI): 2.56–2.58) and diagnosed (1.54; 
95% CI: 1.52–1.56). Among tested individuals above 14 
years-old, the proportion positive was higher in men 
than women for all age groups. Too many tests are per-
formed in women aged 30 years and older, where 49 
of 50 tests are negative. Testing coverage is low (15%) 
among 15 to 24 year-old males. Information on sex and 
age-distribution among the tested helps to interpret 
surveillance data and provides indications on how to 
improve targeting of testing for chlamydia. Regular 
prevalence surveys may address remaining limitations 
of surveillance.
Introduction
Genital Chlamydia trachomatis infection (hereafter: 
chlamydia) is the most frequently reported sexually 
transmitted infection (STI) in Europe, in particular in 
Norway [1,2]. Early diagnosis and treatment has been 
considered a major strategy to prevent complications 
and further transmission of chlamydia [3,4], and coun-
tries have tried various strategies to increase testing 
in target populations [5]. The evidence for the effect 
of early diagnosis and treatment of chlamydia on the 
population level is however weak [6,7].
In Norway, there is no opportunistic or systematic 
screening programme for chlamydia. However, sam-
pling for chlamydia testing is available at no extra cost 
in all general practitioners’ offices, hospitals, STI clin-
ics, students’ clinics, youth clinics (ca 350), and other 
sites. Individuals can also order sampling kits on the 
Internet and send samples to a diagnostic laboratory 
by mail. Since 1995 the following groups are recom-
mended to be tested: any person below 25 years of age 
after each change of sexual partner, individuals with 
clinical symptoms compatible with chlamydia or epide-
miological link to another case, women below 25 years 
of age during antenatal care and women undergoing 
legal abortion [8-12]. Recommendations for annual 
testing of chlamydia and other STIs in men who have 
sex with men were issued in 2005 [11].
Since 2005, laboratories in Norway are mandated to 
report limited data (age and sex) on cases of chla-
mydia infection to the Norwegian Surveillance System 
for Communicable Disease (MSIS) which is owned by 
the Ministry of Health and operated by the Norwegian 
Institute of Public Health (NIPH) [2]. Interpretation of 
chlamydia surveillance data is challenging as many 
asymptomatic cases remain undiagnosed and unre-
ported. The reported number of diagnosed cases is 
thus a result of both the incidence of chlamydia and 
the testing policies and practices. For this reason, we 
augmented the laboratory case-based surveillance 
system [2] with a voluntary collection of the laborato-
ries’ data on sex and age group distribution of all indi-
viduals tested for chlamydia.
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The objective of this study was to describe testing pat-
terns for genital chlamydia infection in Norway and 
incidence of diagnosed genital chlamydia infection in 
order to better understand the chlamydia epidemic and 
improve targeting of chlamydia testing in the future.
Methods
Mandatory surveillance
Before 2005, laboratories reported the aggregated 
number of chlamydia tests performed and the number 
of positive test results on a yearly basis. Since 2005, 
laboratories have been mandated to report case-based 
data in February for the preceding year. The following 
variables are collected for each diagnosed case; date 
of diagnosis, birth year, sex and municipality of resi-
dence [2]. Each case represents one record in an Excel 
file, which is encrypted and password protected and 
sent by mail to NIPH. No unique identifiers are used. 
Clinicians do not report.
A case is defined as a person with one or more posi-
tive laboratory tests for Chlamydia trachomatis in a uri-
nary sample or a sample from anus, cervix, urethra, or 
vagina within a period of 60 days. This case definition 
is used to avoid counting as a new case tests taken 
from multiple sites or a positive test of cure (which up 
until 2013 was universally recommended to be taken 
5–6 weeks after treatment [2], now only if poor compli-
ance is suspected, if symptoms persist, if reinfection is 
probable, or if patient is pregnant [10,11]).
The total number of chlamydia tests performed in a 
year by each laboratory is also collected, using the 
same principles defining a case; ‘one tested’ refers to 
one person with one or more chlamydia tests within a 
period of 60 days. The total number tested (one num-
ber = denominator) during the year is reported in the 
cover letter attached to the Excel file.
Voluntary supplementary data collection
In 2007, we augmented surveillance with a voluntary 
annual aggregate reporting from laboratories of sex 
and age group distribution of all tested. The table is 
sent by email to NIPH. Participation has increased 
year by year. Information on sex and age distribution 
among the tested was received from 10/22 laboratories 
in 2007, 7/22 laboratories in 2008, 13/20 laboratories 
in 2009, 16/19 laboratories in 2010, 17/19 laboratories 
in 2011, 17/19 laboratories in 2012, and in 2013 16/18 
laboratories. For the analyses, we have assumed that 
the age and sex distribution in the non-reporting labo-
ratories was the same as in the reporting laboratories 
and extrapolated these distributions to the reported 
sample of all tested. To justify this assumption, we 
compared the proportion of 20 to 24 year-old women 
among all those tested in one laboratory in its first 
reporting year to the corresponding proportion in all 
the other laboratories reporting that year. We found 
that the difference was usually in the order of zero to 
three per cent points.
Figure 1
Annual genital Chlamydia trachomatis testing rates (per 10,000 population) and diagnosis rates (per 100,000 population), 
Norway, 1990–2013
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Data analyses
We present annual testing rates, diagnosis rates and 
proportion positive for the total population (1990–
2013) and by age group and sex (2007–2013). Yearly 
population data are collected from Statistics Norway. 
For testing of trends, we used a negative binomial 
regression with a year covariate.
Results
Rates of chlamydia diagnosis
Between 1990 and 2013 the annual number of diag-
nosed chlamydia cases in Norway per population was 
multiplied 1.5 times from ca 300 to ca 450 per 100,000 
per year. The sharpest rise in this period corresponded 
to a 1.7 times increase from 293 per 100,000 popula-
tion in 1997 to 496 in 2008. In 2013 the diagnosis rate 
was 454 per 100,000 population (Figure 1). A trend test 
of the diagnosis rate showed an average increase of 
2.2% (95% CI: 1.4–2.9%) each year from 1990 to 2013 
(p-value < 0.001).
For the 2007 to 2013 period, when data on age group 
and sex were available among the tested, the highest 
diagnosis rates were found in 20 to 24 year-old women, 
followed by women aged 15 to 19 years and men aged 
20 to 24 years. In 2010, the diagnosis rate among 
women aged 20 to 24 was 4,151 per 100,000, which is 
equivalent to one in 25 women having been diagnosed 
with chlamydia that year. Apartfor some declines until 
2012 among women aged 15 to 19 years-old (from 2008) 
and 20 to 24 years-old (from 2010), the diagnosis rates 
have been relatively stable in the population for the 
whole period considered (2007–2013). (Figure 2).
Rates of chlamydia testing
The testing rate for chlamydia in Norway was at its 
highest in the beginning of the 1990s with a peak of 
8,035 tested per 100,000 population in 1991. The 
testing rate then decreased yearly and reached 5,312 
tested per 100,000 in year 2000. Since 2000, the test-
ing rate for chlamydia in Norway has been relatively 
stable (Figure 1).
According to the data from 2007 onwards, among indi-
viduals over 14 years-old, women have higher testing 
rates than men in all respective age groups (Figure 3). 
These and age group specific testing rates have been 
relatively stable throughout the 2007 to 2013 period.
The chlamydia testing coverage (defined as the num-
ber of tests divided by the number of individuals in 
the population considered) was 38% (63,679/165,558) 
in women aged 20 to 24 years in 2013 while the cor-
responding figure for men in the same age group 
was 15% (25,167/173,489). In the age group 15 to 19 
years the coverage was 4% (6,687/168,038) and 17% 
(26,834/158,031) for men and women, respectively.
Proportion positive for chlamydia among the 
tested
In 1990 the proportion positive among those tested for 
chlamydia was 4.9% (15,567/320,459). The proportion 
positive among those tested for chlamydia decreased 
to 4.1% (13,033/315,257) in 1993 (when the testing rate 
was 733 per 100,000 population), and increased yearly 
to a peak of 9.1% (22,527/246,268) in 2010 (Figure 4) 
before going down to 8.0% (22,946/286,653) in 2013 
Figure 2
Annual genital Chlamydia trachomatis diagnosis rates 
(per 100,000 population) by age group and sex, Norway, 
2007–2013
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Figure 3
Annual genital Chlamydia trachomatis testing rates (per 
100 population) by age group and sex, Norway, 2007–2013
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The peak in 2010 coincided with a drop by 6.6% in the 
number of people tested.
Throughout the 2007 to 2013 period, the proportions 
of positive test results for chlamydia among men or 
women tested were respectively highest in the young-
est age groups (15–19 years), especially among men 
(Figure 5). In the whole period, there was large varia-
tion in proportion positive, e.g. 17.7% among men aged 
15 to 19 years to 2.1% among women 30 years of age or 
older (Table).
Sex and age distribution among the tested and 
diagnosed
In the 2007 to 2013 period, women made up 72% 
(1,031,667/1,433,258) of those tested for chlamydia 
and 61% (71,538/117,978) of those diagnosed (Table). 
Women were 2.56 times (95% CI: 2.56–2.58) more 
likely to be tested than men and 1.54 times (95% CI: 
1.52–1.56) more likely to be diagnosed. In the age 
group 15 to 19 years, women were 4.56 (95% CI: 4.53–
4.61) times more likely to be tested than men.
The majority of chlamydia tests are taken in persons 
25 years of age and older while the majority of diag-
noses are found in persons younger than 25 years. 
Among women, 45% (466,655/1,031,667) of the tested 
were less than 25 years-old while 75% (53,407/71,538) 
of the diagnosed were below this age. Men under 25 
years-old represented 38% (153,033/401,591) of all 
tested men and 56% (26,090/46,440) of all diagnosed 
men (Table). For women aged 30 years and older, only 
2.1% (7,270/349,385) of those tested were positive, 
which corresponds to 49 of 50 tests in this age group 
being negative. The sex and age distribution among 
the tested has remained stable throughout this seven 
year period.
Discussion
We have found that information on age group and sex 
among those who are tested for chlamydia helps us 
interpret the results obtained by the national surveil-
lance system for chlamydia. The proportion positive 
among the tested rose twofold from around 4% in the 
1990s to 8% in 2013 whereas the number of diagnosed 
cases per population was multiplied 1.5 times from ca 
300 to ca 450 per 100,000 per year in the same period. 
One possible explanation is that the true incidence 
and prevalence of chlamydia has indeed increased. 
Recommendations for chlamydia testing were issued in 
1995 [12]. Another possible explanation could therefore 
be that chlamydia testing, which has been reduced dur-
ing the study period (ca 7,500 annual tests per 100,000 
in 1990 to 5,500 in 2013), has become more targeted at 
Figure 4
Annual rates of genital Chlamydia trachomatis testing (per 100,000 population) and annual proportion of positive test 
results, Norway, 1988–2013
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high-prevalence groups so that the proportion positive 
among the tested has increased. Finally, the introduc-
tion of more sensitive diagnostic methods in the late 
1990s may have contributed to the increase in positiv-
ity. An association was found between the introduc-
tion of nucleic acid amplification test (NAAT) and the 
proportion positive for chlamydia among the tested in 
Norway [2]. However, as the positivity rate continued 
to rise even after the introduction of NAAT, other fac-
tors may be have been more important to explain the 
observed increase, such as secular trend and case mix 
among the tested .
The value of testing data
The surveillance data reflects the sex distribution 
among those who get tested for chlamydia in Norway. 
Among persons below 25 years of age, more women 
get tested, thus more women get diagnosed with chla-
mydia than men. Women aged 20 to 24 years constitute 
the group with the highest testing and diagnosis rates 
for chlamydia in Norway. The testing rates among the 
males in this age group are lower, hence, the incidence 
rates are lower. More women than men get tested 
also among persons above 25 years of age, but the 
sex distribution among the diagnosed is more equal. 
Among those over 14 years-old, the proportion positive 
is higher among men than women in all age groups, 
which probably reflects that men who are offered or 
choose to get tested for chlamydia are more at risk of 
infection (partner tracing, symptoms, men who have 
sex with men), not that the chlamydia prevalence is 
higher in men than in women [13].
Proportion positive among the tested is an important 
supplement that helps us understand the observed 
results of diagnosed chlamydia cases. In the early 
2000s, the positivity rate increased in parallel to the 
rise in diagnosis rate. These increases could not be 
explained by more testing in this period as this was 
rather stable. Since 2007, we have observed a decline 
in diagnosed cases among the 15 to 19 year-olds, espe-
cially among girls. Testing data show that this decline 
only partly can be attributed to less testing in this age 
group. The proportion positive has also decreased 
in the same period. This could indicate that the chla-
mydia prevalence in this age group has dropped. It 
could, however, also indicate that that we do not reach 
those most at risk in this age group. There are no avail-
able data to support a change is sexual behaviour or 
in chlamydia prevalence for the youngest age group in 
this period. A decline in diagnosed cases among those 
below 25 years of age has also been observed in our 
neighbouring country Denmark since 2009 [14].
Comparison with other countries
The testing rate (and diagnosis rate) in Norway is simi-
lar to the testing rates in Sweden and Denmark. In 
2012, the testing rates per 100,000 total population 
was 4,862 and 6,087 in Sweden and Denmark respec-
tively (5,461 in Norway) [14,15]. The sex distribution 
among the tested is also comparable [16]. In several 
other European countries, the reported testing rates 
are much lower [5]. Comparing testing rates in different 
European countries is however challenging due to the 
variation of systems collecting data on the number of 
tested.
How data on chlamydia testing help us further 
target testing
Testing data show that Norwegian women between 20 
and 24 years-old adhere to the recommendations for 
testing. In this group, the testing rate corresponds to 
coverage of close to 40% if there were no repeat test-
ing, compared with 14% for men in the same age group. 
The chlamydia testing coverage in England in 2012 for 
the 15 to 24 year-old age group was 35% for women and 
15% for men [17]. Corresponding figures from Norway 
were 28% and 9% for women and men, respectively. 
A register study from Central Norway (1990–2003) 
showed that 85% of women had had at least one chla-
mydia test before the age of 25 years [18]. More than 
half of these were registered with two or more tests 
within an observation period of maximum four years. 
The results confirm a high coverage of chlamydia test-
ing among women in their early twenties [18].
One possible explanation for the sex difference could 
be that women take more concern for their sexual 
health, for instance seeking guidance for birth con-
trol, and therefore have a more active health seeking 
behaviour than men. Supporting this assumption are 
two Norwegian studies showing that women diagnosed 
with chlamydia are more likely to get their prescribed 
treatment than men diagnosed with chlamydia [19,20].
Figure 5
Proportion of positive for genital Chlamydia trachomatis 
among persons tested, by age group and sex, Norway, 
2007–2013
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In the youngest age group (15–19 years) the testing rate 
is lower. The results of different sexual behaviour stud-
ies conducted in the period between 1987 and 2006 
in Norway inform of a mean age of sexual debut vary-
ing from 16 to 18 years, lower for women than men and 
decreasing over time [13,21,22]. Many young people in 
this age group are not yet sexually active and at risk 
of chlamydia. This may contribute to a lower testing 
rate in this age group. The high positivity rate among 
the tested in this age group may indicate that testing 
occurs among those at high risk.
The majority of tests are performed in persons 25 years 
and above while the majority of the diagnosed cases 
are found in the younger age groups. Among women 
above 30 years-old the proportion positive is very low. 
Widespread testing in such a low prevalence popula-
tion means waste of resources and low predictive value 
of a positive test result. Situations where unnecessary 
chlamydia testing outside the recommended indica-
tions could take place are when women above 30 have 
a smear test taken as part of the cancer screening pro-
gramme (every third year [23]), during consultations for 
contraception and during antenatal care.
The high proportion positive among men between 25 
and 40 years-old (12% in men aged 25–29 years) indi-
cates that chlamydia testing is rather well targeted and 
not only routine testing in this group. Patients diag-
nosed with chlamydia have the responsibility to coop-
erate in partner tracing, according to the Norwegian 
Infectious Disease Control Act [24]. Although indica-
tions for testing are not known, partner tracing is likely 
to be a common indication for testing. A study from 
Sweden showed that partner tracing was the most 
common reason for testing among men [16]. Due to the 
lack of prevalence surveys, we do not know if the chla-
mydia prevalence is higher among men than women in 
this age group. However, studies from other countries 
have shown that the peak prevalence age among men 
is higher than among women [25]. Along with the high 
proportion positive found among men of 25 to 29 years 
of age, this could be an incentive to explore whether 
recommendations for chlamydia testing also should 
include men up to 30 years.
Use of selective screening criteria to increase the 
diagnostic yield among the tested, even within the 
groups recommended for chlamydia testing, has not 
been applied in Norway. Such approach may be valu-
able [26,27] although selective screening criteria have 
shown difficult to identify [28,29].
Limitations
Data on chlamydia testing has improved our under-
standing of the chlamydia surveillance data and of how 
targeted chlamydia testing is. However, these data 
merely reflect who gets an offer or decides to get tested 
and do not necessarily bring us closer to the real chla-
mydia distribution in the population. We do not know 
which healthcare providers have ordered the tests or 
their indications. This could have provided useful infor-
mation to explain the sex differences in testing rates.
The case definitions used for both a diagnosed case 
and a tested person include only one count within a 
period of 60 days. In the absence of a unique identi-
fier, this is done to avoid counting twice those who 
take samples from more than one site or who return for 
a test of cure. There is a problem with both the sensi-
tivity and specificity of this case definition as 60 days 
is a longer time period than the recommendations for 
test of cure. If a person is re-infected within a period 
of 60 days, it will not be counted as a double incident 
of chlamydia, only one. The extent of possible double 
reporting or underreporting of double chlamydia inci-
dents is not known.
Age groups 
in years
Women Men
Number 
tested
Proportion 
of all 
women 
tested (%)
Number 
diagnosed
Proportion 
of all 
women 
diagnosed 
(%)
Proportion 
positive 
(%)
Number 
tested
Proportion 
of all men 
tested (%)
Number 
diagnosed
Proportion 
of all men 
diagnosed 
(%)
Proportion 
positive (%)
0–14 2,743 0.3 94 0.1 3.4 810 0.0 16 0.0 2.0
15–19 144,525 14.0 20,645 28.8 14.3 33,616 8.4 5,935 12.8 17.7
20–24 319,380 31.0 32,668 45.6 10.2 118,607 29.5 20,139 43.3 17.0
25–29 215,625 20.9 10,861 15.2 5.0 91,983 22.9 10,776 23.2 11.7
≥ 30 349,385 33.9 7,270 10.2 2.1 156,575 39.0 9,574 20.6 6.1
Total 1,031,667 100 71,538 100 6.9 401,591 100 46,440 100 11.6 
< 25 466,656 45.2 53,407 74.6 11.4 153,033 38.1 26,090 56.1 17.0
≥ 25 565,011 54.8 18,131 25.3 3.2 248,559 61.9 20,350 43.8 8.2
Total 1,031,667 100 71,538 100 6.9 401,591 100 46,440 100 11.6
Table
Number and proportion tested and diagnosed for genital Chlamydia trachomatis by age group and sex, Norway, 2007–2013
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Due to the absence of a unique identifier and the 
aggregation of test data, we are also not able to detect 
re-testing or re-infections with our surveillance system. 
As testing for chlamydia is recommended in the under 
25 year-olds between each partner change, probably, 
some individuals are tested more than once per year. 
Therefore, converting an annual age group specific 
testing rate to a testing coverage in that age group 
probably leads to overestimated coverage percent-
ages. Currently, there are no recommendations for re-
testing in Norway.
We have extrapolated the sex and age distribution 
from the reported sample to all tested. This may intro-
duce bias if the sex and age distribution of those who 
get tested correlates with characteristics in the unre-
ported sample – for example with geographical area. 
Fortunately, the completeness of data on testing has 
increased to over 90% in the last few years, reducing 
the possibility for bias.
Conclusion
Augmenting case-based chlamydia surveillance with 
aggregated data on age group and sex of all who have 
been tested helps in the interpretation of surveillance 
data. We have found that more women than men are 
tested for chlamydia in Norway. This partly explains 
the higher diagnosis rates among women. Too many 
tests are performed in groups with very low prevalence 
of infection, giving a very low yield. Still, surveillance 
data reflect those who get tested, and not necessarily 
the real distribution of cases. Regular population based 
prevalence surveys would be a useful supplement.
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